328107-22-8

Basic information

• Product Name: 3-AMINO-N-(3-TRIFLUOROMETHYL-PHENYL)-BENZAMIDE
• Synonyms: AKOS BBS-00006428;3-AMINO-N-(3-TRIFLUOROMETHYL-PHENYL)-BENZAMIDE
• CAS NO: 328107-22-8
• Molecular Formula: C₁₄H₁₁F₃N₂O
• Molecular Weight: 280.25
• Mol File: 328107-22-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-AMINO-N-(3-TRIFLUOROMETHYL-PHENYL)-BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-AMINO-N-(3-TRIFLUOROMETHYL-PHENYL)-BENZAMIDE(328107-22-8)
• EPA Substance Registry System: 3-AMINO-N-(3-TRIFLUOROMETHYL-PHENYL)-BENZAMIDE(328107-22-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 328107-22-8(Hazardous Substances Data)

Upstream product

• 98-16-8 3-trifluoromethylaniline 
• 121-90-4 m-nitrobenzoic acid chloride 
• 121-92-6 3-nitrobenzoic acid 
• 180631-67-8 3-nitro-N-(3-(trifluoromethyl)phenyl)benzamide 

Relevant articles and documents

2-Amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide derivates

The invention relates to compound characterized by a general formula (1), wherein n of R1n is 0, 1, 2, 3 or 4, in particular n of R1n is 0 or 1, and each R1 independently from any other R1

Cyclooxygenase-1-selective inhibitors are attractive candidates for analgesics that do not cause gastric damage. Design and in vitro/in vivo evaluation of a benzamide-type cyclooxygenase-1 selective inhibitor

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities. Here, we report that N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (18f, TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC 50 = 0.80 ± 0.05 μM, COX-2 IC50 = 210 ± 10 μM). This compound causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. Our results show that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.